ArticleJournal of Korean medical science2026
Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
backgroundTisagenlecleucel, a CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy, has shown durable efficacy in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). However, comparative real-world data against standard-of-care (SOC) therapies remain scarce in Asian populations.
methodsWe performed a retrospective, propensity score-matched cohort study at two tertiary hospitals in Korea. Adult patients with R/R DLBCL treated in the third-line (3L) or later setting received either tisagenlecleucel (CAR-T cohort) or SOC salvage chemoimmunotherapy. Propensity score matching (1:1) was conducted using age, sex, line of therapy, International Prognostic Index, Eastern Cooperative Oncology Group status, and year of diagnosis. Outcomes included response rates, progression-free survival (PFS), overall survival (OS), and safety.
resultsAmong 178 eligible patients (CAR-T, n = 67; SOC, n = 111), 100 were matched (50 per group). The CAR-T cohort achieved a significantly higher overall response rate (68% vs. 28%) and complete response rate (60% vs. 22%). Median PFS was 4.8 months for CAR-T vs. 1.6 months for SOC (hazard ratio [HR], 0.49;
conclusionIn this real-world propensity score-matched comparison from Asia, tisagenlecleucel demonstrated superior survival and response outcomes compared with SOC salvage chemotherapy in Korean patients with R/R DLBCL, supporting its role as the standard of care in the ≥ 3L setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.